Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

Next Previous
Trial Profile

A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IRX 2 (Primary) ; Cyclophosphamide; Indometacin; Multivitamin; Omeprazole; Zinc
  • Indications Head and neck cancer; Mouth neoplasm; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms INSPIRE
  • Sponsors Ernexa Therapeutics; Eterna Therapeutics; IRX Therapeutics

Most Recent Events

  • 25 Mar 2025 According to a Ernexa Therapeutics media release, the Eterna Therapeutics has changed its name to Ernexa Therapeutics.
  • 07 May 2023 Status changed from active, no longer recruiting to completed.
  • 26 Jul 2022 According to a Brooklyn ImmunoTherapeutics media release, the company expects to present he results of the INSPIRE study at a scientific conference later this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top